Synthesis of tritium-labeled levetiracetam ((2S)-2-(2-oxopyrrolidin-1-yl) butanamide) with high specific activity

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 55, Issue 1, 2012, Pages 48-51

  Hildenbrand, Simone ^a   Baqi, Younis ^a   Müller, Christa E ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

epilepsy; high specific activity; levetiracetam; SV2A protein; tritium labeling

Indexed keywords

BINDING SITES; BIOSYNTHESIS;

BINDING-SITES; EPILEPSY; HIGH SPECIFIC ACTIVITIES; LABELINGS; LEVETIRACETAM; MEMBRANE PREPARATION; RADIOLIGANDS; RATS BRAIN; SV2A PROTEIN; TRITIUM LABELING;

TRITIUM;

ETIRACETAM; RADIOLIGAND; TRITIUM;

ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; DRUG BINDING SITE; DRUG SYNTHESIS; ISOTOPE LABELING; NONHUMAN; RAT;

RATTUS;

EID: 84856316140     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1942     Document Type: Article

References (10)

1. W. Löscher, D. Hönack, C. Rundfeldt, J. Pharmacol. Exp. Ther. 1998, 284, 474-479.
2. S. Shorvon, Lancet 2001, 358, 1885-1892.
3. B. A. Lynch, N. Lambeng, K. Nocka, P. Kensel-Hammes, S. M. Bajjalieh, A. Matagne, B. Fuks, Proc. Natl. Acad. Sci. USA 2004, 101, 9861-9866.
4. M. Noyer, M. Gillard, A. Matagne, J.-P. Hénichart, E. Wülfert, Eur. J. Pharmacol. 1995, 286, 137-146.
5. M. Gillard, B. Fuks, P. Michel, P. Vertongen, R. Massingham, P. Chatelain, Eur. J. Pharmacol. 2003, 478, 1-9.
6. M. Gillard, B. Fuks, K. Leclercq, A. Matagne, Eur. J. Pharmacol. 2011, 664, 36-44.
7. M. E. F. Braibante, H. T. S. Braibante, A. F. Morel, C. C. Costa, M. G. Lima, J. Braz. Chem. Soc. 2006, 17, 184-188.
8. K. Das Sarma, J. Zhang, Y. Huang, J. G. Davidson, Eur. J. Org. Chem. 2006, 37, 3730-3737.
9. V. J. Harding, R. M. MacLean, J. Biol. Chem. 1916, 25, 337-350.
10. P. V. R. Acharyulu, C. M. H. Raju, PCT Int. Appl. US 2005/0182262 A1, 2005.